GRI Bio Faces Delisting Concerns
Ticker: GRI · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1824293
Sentiment: bearish
Topics: delisting, listing-rules, regulatory
TL;DR
GRI Bio might get kicked off the exchange - big trouble.
AI Summary
GRI Bio, Inc. filed an 8-K on March 10, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and has its principal executive offices in La Jolla, California.
Why It Matters
This filing indicates potential issues with GRI Bio's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former name
- March 10, 2025 (date) — Date of earliest event reported
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific listing rule or standard has GRI Bio, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that GRI Bio, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 10, 2025.
What was GRI Bio, Inc.'s former name?
GRI Bio, Inc.'s former name was Vallon Pharmaceuticals, Inc.
In which state is GRI Bio, Inc. incorporated?
GRI Bio, Inc. is incorporated in Delaware.
What is the address of GRI Bio, Inc.'s principal executive offices?
The address of GRI Bio, Inc.'s principal executive offices is 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding GRI Bio, Inc. (GRI).